0000950170-24-069281.txt : 20240605
0000950170-24-069281.hdr.sgml : 20240605
20240605160506
ACCESSION NUMBER: 0000950170-24-069281
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240603
FILED AS OF DATE: 20240605
DATE AS OF CHANGE: 20240605
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: White William Richard
CENTRAL INDEX KEY: 0001778739
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39438
FILM NUMBER: 241021964
MAIL ADDRESS:
STREET 1: C/O AKERO THERAPEUTICS, INC.
STREET 2: 170 HARBOR WAY 2ND FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Disc Medicine, Inc.
CENTRAL INDEX KEY: 0001816736
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 851613057
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 321 ARSENAL STREET, SUITE 101
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: (617) 674-9274
MAIL ADDRESS:
STREET 1: 321 ARSENAL STREET, SUITE 101
CITY: WATERTOWN
STATE: MA
ZIP: 02472
FORMER COMPANY:
FORMER CONFORMED NAME: Gemini Therapeutics, Inc. /DE
DATE OF NAME CHANGE: 20210209
FORMER COMPANY:
FORMER CONFORMED NAME: FS Development Corp.
DATE OF NAME CHANGE: 20200702
4
1
ownership.xml
4
X0508
4
2024-06-03
0001816736
Disc Medicine, Inc.
IRON
0001778739
White William Richard
C/O DISC MEDICINE, INC.
321 ARSENAL STREET, SUITE 101
WATERTOWN
MA
02472
true
false
false
false
true
Common Stock
2024-06-03
4
M
false
1756
2.65
A
1756
D
Common Stock
2024-06-03
4
M
false
201
9.86
A
1957
D
Common Stock
2024-06-03
4
S
false
107
35.1469
D
1850
D
Common Stock
2024-06-03
4
S
false
1755
36.1020
D
95
D
Common Stock
2024-06-03
4
S
false
95
36.7208
D
0
D
Stock Option (Right to Buy)
2.65
2024-06-03
4
M
false
1756
0.00
D
2030-11-26
Common Stock
1756
3512
D
Stock Option (Right to Buy)
9.86
2024-06-03
4
M
false
201
0.00
D
2031-09-13
Common Stock
201
3010
D
The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on December 13, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.54 to $35.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.575 to $35.565, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.655 to $36.77, inclusive.
The shares underlying this option vest in 16 equal quarterly installments following November 27, 2020, subject to the Reporting Person's continued service on each such vesting date.
The shares underlying this option vest in 48 equal monthly installments following September 1, 2021, subject to the Reporting Person's continued service on each such vesting date.
By: /s/ Rahul Khara, as Attorney-in-Fact
2024-06-05